EHS
EHS

STAT+: OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking



Noted biotech investment firm OrbiMed slid from first place to 14th in STAT’s latest annual ranking of venture capital firm performance.

OrbiMed, which is based in New York City, is one of the most prominent players in the health care investing world. It manages $18 billion in assets, some of which the firm has invested in startups like Acceleron Pharma, which was acquired by Merck last year for $11.5 billion.

Continue to STAT+ to read the full story…



Source link

EHS
Back to top button